Gideon Bollag, Opna Bio CEO
Plexxikon vets kick off new drug discovery outfit — with old assets and new target
Daiichi Sankyo shut down its South San Francisco subsidiary Plexxikon earlier this year. Now a new startup is looking to forge its own path …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
